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PGenetics and Statin Effects
The SLCO1B1*5 Genetic Variant Is
Associated With Statin-Induced Side Effects
Deepak Voora, MD,*‡ Svati H. Shah, MD, MHS,*†‡ Ivan Spasojevic, PHD,‡ Shazia Ali, PHARMD,§
Carol R. Reed, MD,¶ Benjamin A. Salisbury, PHD,¶ Geoffrey S. Ginsburg, MD, PHD*‡§
Durham, North Carolina; and New Haven, Connecticut
Objectives We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects.
Background Statin-induced side effects can interfere with therapy. Single nucleotide polymorphisms in cytochrome P450 en-
zymes impair statin metabolism; the reduced function SLCO1B1*5 allele impairs statin clearance and is associ-
ated with simvastatin-induced myopathy with creatine kinase (CK) elevation.
Methods The STRENGTH (Statin Response Examined by Genetic Haplotype Markers) study was a pharmacogenetics study
of statin efficacy and safety. Subjects (n  509) were randomized to atorvastatin 10 mg, simvastatin 20 mg, or
pravastatin 10 mg followed by 80 mg, 80 mg, and 40 mg, respectively. We defined a composite adverse event
(CAE) as discontinuation for any side effect, myalgia, or CK 3 upper limit of normal during follow-up. We se-
quenced CYP2D6, CYP2C8, CYP2C9, CYP3A4, and SLCO1B1 and tested 7 reduced function alleles for associa-
tion with the CAE.
Results The CAE occurred in 99 subjects (54 discontinuations, 49 myalgias, and 9 CK elevations). Sex was associated
with CAE (percent female in CAE vs. no CAE groups, 66% vs. 50%, p  0.01). SLCO1B1*5 was associated with
CAE (percent with 1 allele in CAE vs. no CAE groups, 37% vs. 25%, p  0.03) and those with CAE with no sig-
nificant CK elevation (p  0.03). Furthermore, there was evidence for a gene-dose effect (percent with CAE in
those with 0, 1, or 2 alleles: 19%, 27%, and 50%, trend p  0.01). Finally, the CAE risk appeared to be greatest
in those carriers assigned to simvastatin.
Conclusions SLCO1B1*5 genotype and female sex were associated mild statin-induced side effects. These findings expand
the results of a recent genome-wide association study of statin myopathy with CK 3 normal to milder, statin-
induced, muscle side effects. (J Am Coll Cardiol 2009;54:1609–16) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.053n
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dtatins are widely prescribed medications for the prevention
f myocardial infarction and stroke, and their use also
educes cardiovascular mortality (1). Despite their proven
fficacy, 25% to 50% of patients with coronary artery disease
re noncompliant with statin medications after 1 year (2).
lthough a multifactorial problem, many believe that statin
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ccepted April 13, 2009.oncompliance is primarily caused by side effects (3). In
umerous placebo-controlled clinical trials, statins have a
ell-defined safety profile with a small but real risk of
redominantly musculoskeletal side effects of increasing
everity, for example, myalgia, creatine kinase (CK) elevations,
nd rhabdomyolysis (1). In clinical practice the incidence of
ild statin-induced side effects appears to be greater than that
een in controlled trials and is estimated at 5% to 10% (4).
See page 1617
his discrepancy is unexplained. However, it is the consen-
us that these symptoms can be caused by statins, often in
he absence of CK elevations (5). This consensus is sup-
orted by observations that statin-induced side effects ap-
ear to be a class effect (5), improve with withdrawal of the
rug, and recur with rechallenge of the drug (6).
Although the mechanisms for these side effects arenclear, certain patient characteristics have been identified
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as lower body mass, female sex,
and hepatic or renal dysfunction
(7). Several authors have identi-
fied that these side effects are
dose dependent (8), are increased
by concomitant drugs that impair
statin disposition and metabo-
lism (8), and are associated with
elevated levels of statin metabo-
lites (6). Furthermore, SNPs that
impair the activity of drug-
metabolizing enzymes (9) have
been associated with the devel-
opment of musculoskeletal side
ffects. In particular, the *5 allele (Val174Ala, rs4149056) in
he hepatic drug transporter SLCO1B1 interferes with
ocalization of the transporter to the plasma membrane (10)
nd leads to greater systemic statin concentrations (11–13).
he *5 allele was identified in a genome-wide association
tudy as a dominant cause of severe statin-induced myop-
thy (defined as CK 10 the upper limit of normal in
hose with symptoms and3 in those without symptoms)
n patients taking 80 mg of simvastatin (14). Whether the
LCO1B1*5 and other SNPs in drug-metabolizing enzymes
re responsible for milder side effects caused by statins other
han simvastatin is unknown.
Therefore, we sought to test the hypothesis that common
enetic polymorphisms that lead to reduced function in
rug metabolizing or transporting enzymes would be asso-
iated with mild statin-induced side effects, particularly
hose without CK elevations. We tested this hypothesis in
he context of a large pharmacogenetics trial of 3 commer-
ially available statins, the STRENGTH (Statin Response
xamined by Genetic Haplotype Markers) study, where the
ain objectives were to identify genetic associations with
tatin safety and efficacy.
ethods
tudy population. The STRENGTH study was a phar-
acogenetic study of statin efficacy and safety (15). In brief,
t was a 16-week, randomized, open-label study of 3 statins
ested in 509 outpatients with hypercholesterolemia con-
ucted between 2001 and 2002. Subjects were randomly
ssigned to 8 weeks of 10 mg/day atorvastatin, 20 mg/day
imvastatin, or 10 mg/day pravastatin followed by 8 weeks
f 80 mg/day atorvastatin, 80 mg/day simvastatin, and 40
g/day pravastatin, respectively.
The following 57 subjects were excluded from all analyses
s the result of incomplete follow-up: 10 withdrew consent
efore drug administration, 21 discontinued therapy for
easons not related to symptoms, 13 were lost to follow-up,
were removed for protocol violations or noncompliance
Abbreviations
and Acronyms
AE  adverse event
CAE  composite adverse
event
CK  creatine kinase
FDR  false discovery rate
LDL  low-density
lipoprotein
MAF  minor allele
frequencies
SNP  single nucleotide
polymorphismith study drug, 1 for pregnancy, and 5 for other reasons. Collow-up, laboratory testing, and definition of primary
utcome. In-person visits with a research coordinator were
cheduled every other week to assess for adverse events
AEs) and compliance. Any symptom, physical sign, syn-
rome, or disease that either emerged during the study or, if
resent at screening, worsened during the study, regardless
f the suspected cause of the event was documented as a
otential adverse event. Symptoms may have been volun-
eered spontaneously by the subject or discovered as a result
f general questioning by the study staff or by physical
xamination.
At each visit the subject was asked, “Have you experi-
nced any problems since your last visit?” To avoid vague,
mbiguous, or colloquial expressions, staff recorded all
ymptoms in standard medical terminology in addition to
he subject’s own words. For example, symptoms were
ecorded as “myalgia,” “muscle cramps,” or “elevated creat-
ne phosphokinase” as appropriate. At both the first and
nal visit (week 16 or at time of termination) a thorough
hysical examination was performed and any significant
hange that occurred during the trial recorded as a potential
E. Finally, in addition to these assessments, at the
ollowing intervals routine laboratory analyses for chemis-
ries, liver function studies, and CK were measured: baseline
nd weeks 6, 8, 12, and 16.
For this analysis, we prospectively defined the primary
utcome as a composite adverse event (CAE) of any of
he following at any time point in the study: 1) premature
iscontinuation of study drug due to any side effect;
) myalgia/muscle cramps (irrespective of CK values);
nd 3) CK elevations 3 the upper limit of normal
irrespective of symptoms).
andidate gene selection, power calculation, and SNP
election. As part of the STRENGTH protocol, 160
otential candidate genes were sequenced or genotyped as
reviously described (15). For the purposes of this focused
nalysis, from this list of candidate genes we selected 5 genes
CYP2D6, CYP2C8, CYP2C9, CYP3A4, and SLCO1B1)
hought to be implicated in statin pharmacokinetics based
n information compiled by the PharmGKB database (16)
nd recent reviews of statin pharmacogenetics pathways
17). The percent missing genotypes and race stratified tests
or Hardy-Weinberg Equilibrium were evaluated by the use
f Haploview software (18) as a means of quality control.
he average call rate was 98%.
We prospectively defined allele frequency cutoffs based on
ower calculations performed by using the QUANTO
rogram (19). On the basis of the 99 subjects with the CAE
ncluded in our primary analysis, assuming a relative risk of
.0 associated with the risk allele and a dominant model, we
stimated that we would have 50% power with minor allele
requencies (MAF) of 0.05, 73% power with MAF of 0.10,
2% power with MAF of 0.15, and 85% power with MAF
f 0.20. On the basis of these estimates, we chose to include
nly those alleles with frequencies 0.10 in STRENGTH
aucasian patients for further analysis. Finally, because we
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October 20, 2009:1609–16 Pharmacogenetics of Statin Side Effectsere primarily interested in those genes implicated in statin
harmacokinetics, we limited our analysis to functional
NPs (i.e., those with alleles that had been previously tested
n vivo or in vitro and found to reduce the enzymatic
unction of the protein) (10,20).
tatin metabolite measurements. Simvastatin and prav-
statin metabolites were measured on plasma collected
rom samples collected the day after the last low- or high-
ose statin was taken. We randomly chose 57 subjects
ssigned to simvastatin and 55 assigned to pravastatin
ith available samples, stratified 1:1 based on SLCO1B1
enotype and sex. Metabolites were analyzed by liquid
hromatography tandem mass spectrometry system as
reviously described (21) with modifications (see Online
ethods for details). The lower limits of quantification
n plasma were as follows: 0.018, 0.018, 0.041, and 0.041
g/ml for simvastatin acid, simvastatin lactone, pravasta-
in acid, and pravastatin lactone, respectively. In 2
imvastatin and 6 pravastatin samples, metabolites of
oth lactone and acid were undetectable (suggesting
onadherence) and were excluded. In addition, 3 simva-
tatin and 1 pravastatin high-dose measurements were
5% of their respective low-dose concentrations (in
ontrast to the remainder of the group, whose high-dose
easurements were 4- to 8-fold greater than their low-
ose measurement), suggesting nonadherence at high
ose and therefore were also excluded from further
nalysis.
tatistical analysis. Continuous variables were compared
ith the use of Student t tests, categorical variables were
ompared with the use of chi-square tests, and trends across
rdinal variables were assessed with the Cochran-Armitage
rend test. Triglycerides and CK values were log-
ransformed to approximate normal distributions. Multivar-
ate models were constructed by the use of logistic regression
or categorical variables. A generalized linear model with the
east square means method was used to estimate percent
eduction in LDL by genotype. For changes in CK
hroughout the study, a repeated measures analysis of
ariance was used. To account for the multiple comparisons,
e calculated the false discovery rate (FDR) as described by
enjamini and Hochberg (22).
Statin metabolite concentrations were log transformed to
pproximate a normal distribution. Generalized linear mod-
ls were constructed to evaluate the association between
enotype (coded as 1, 2, 3) or sex and the log-transformed
rug metabolite concentrations. For each model, residual
lots were examined to confirm a normal distribution of
rrors. No influential outliers were observed.
A p value 0.05 was considered significant for all
nalyses except for interaction tests, where we used a p value
0.2 to allow greater power to detect interactions as
uggested by Selvin (23) and Frankel et al. (24). We used
AS version 9.1 (SAS Institute, Cary, North Carolina) for
ll analyses. Sesults
t total of 452 subjects (88% of total STRENGTH
articipants) received study drug and were available for
ollow-up. During the course of the study, 99 (22%) met at
east 1 criterion for the CAE, with 54 discontinuing drug
or any side effect, 61 developing myalgias/muscle cramps,
nd 9 developing CK elevations 3 the upper limit of
ormal. The baseline characteristics of the entire cohort and
hose with and without the CAE are described in Table 1.
f these characteristics, only sex was significantly different
etween groups with or without the CAE, with a greater
ercentage of female subjects in the CAE group (odds ratio
OR]: 2.0, 95% confidence interval [CI]: 1.2 to 3.1, p 
.004). Importantly, assigned statin type was not associated
ith the CAE (p  0.9). Seven genetic variants in the 5
andidate genes (Table 2) met the analysis criteria of having
minor allele frequency 0.10 that were also known to
educe enzymatic function. One SNP (CYP3A4*1b) devi-
ted significantly from Hardy-Weinberg equilibrium in
aucasian controls (p  0.002); however, the magnitude
f the deviation was small, and therefore the SNP was
etained for statistical analysis. When these 7 SNPs were
ested in dominant models, one SNP in SLCO1B1
SLCO1B1*5, rs4149056, V174A) was associated with
he CAE during the STRENGTH trial (chi-square 
.2, p  0.03, FDR  0.24). In multivariate analyses
djusted for race, female sex and SLCO1B1*5 genotype
ere independently associated with the CAE (OR: 2.2,
aseline Characteristics ofTRENGTH Cohort Stratified by the CAETable 1 B seline Characteristics ofSTRENGTH Cohort Stratified by the CAE
Characteristic
Entire Cohort
(n  452)
CAE
(n  99)
No CAE
(n  353)
Age, yrs (SD) 56 (10) 58 (10) 56 (11)
Sex, n (%)
Male 209 (46) 33 (33) 176 (50)
Female 243 (54) 66 (67)* 177 (50)
Body mass index, kg/m2 (SD) 29.1 (5.2) 29.1 (4.7) 29.1 (5.4)
Smoking status, n (%)
Smoker 84 (19) 18 (18) 66 (19)
Nonsmoker 368 (81) 81 (82) 287 (81)
Race, n (%)
Caucasian 389 (86) 87 (89) 300 (85)
African American 22 (5) 3 (3) 19 (5)
Other 43 (9) 9 (8) 44 (10)
Total cholesterol, mg/dl (SD) 258 (32) 263 (32) 256 (32)
LDL, mg/dl (SD) 173 (25) 176 (24) 173 (26)
HDL, mg/dl (SD) 49 (13) 51 (13) 48 (12)
Triglycerides, mg/dl (SD) 177 (68) 182 (73) 176 (66)
Baseline creatinine kinase, U/l (SD) 121 (81) 123 (94) 121(71)
Assigned statin, n (%)
Atorvastatin 147 (32) 31 (31) 116 (33)
Simvastatin 162 (36) 37 (37) 125 (35)
Pravastatin 143 (32) 31 (31) 112 (32)
ll comparisons are between those with and without the CAE. *p  0.004.
CAE  composite adverse event; HDL  high-density lipoprotein; LDL  low-density lipoprotein;
TRENGTH  Statin Response Examined by Genetic Haplotype Markers.
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Pharmacogenetics of Statin Side Effects October 20, 2009:1609–165% CI: 1.4 to 3.6, p  0.001 and OR: 1.7, 95% CI:
.04, 2.8, p  0.03, respectively). When we analyzed the
ndividual components of the CAE, we observed that
rug discontinuation attributable to a side effect was the
rimary determinant of the associations for SLCO1B1*5
nd female sex with the CAE (p  0.05 for both).
A previous study (12) has demonstrated that there is a
ene dose effect with the SLCO1B1*5 allele in relationship
o statin drug concentrations. Therefore, we sought to find
similar relationship with the CAE. In the STRENGTH
tudy, we found that there indeed was evidence for a
ene-dose effect: the proportion of individuals with the
AE increased with increasing numbers of the SLCO1B1*5
isk allele. For noncarriers (n  325), carriers of 1 allele
n  115), and carriers of 2 alleles (n  8) the proportions
ith the CAE were 0.19 (95% CI: 0.15 to 0.24), 0.27
95% CI: 0.19 to 0.36), and 0.50 (95% CI: 0.16 to 0.84),
espectively (1-sided trend p  0.01).
Sequencing SLCO1B1 in the STRENGTH study iden-
ified 8 additional polymorphisms with MAF 1% in
TRENGTH Caucasians. When these additional SNPs
ere tested individually for their association with the CAE,
SNP in the 13th intron, rs4149080, provided a stronger
ssociation with the CAE (chi-square  7.5, p  0.006)
ompared with SLCO1B1*5; however, there was significant
inkage disequilibrium between rs4149080 and SLCO1B1*5
r2  0.85) in STRENGTH Caucasian subjects.
Because of the 2-stage trial design, we also examined the
iming of the occurrence of CAE with respect to sex and
LCO1B1 genotype. Of the 99 subjects who developed
AE, many (n  61, 62%) developed these during the first
weeks of the trial during the low-dose phase. When
estricting the analysis of the CAE to the low-dose phase of
he trial, female sex and SLCO1B1*5 genotype continued to
e associated with the CAE (p  0.009 and p  0.03,
espectively).
Because of the randomized drug allocation, we also
bserved the proportions with the CAE with respect to
LCO1B1*5 carrier status and sex stratified by assigned drug
reatment (Fig. 1). Subjects who carried at least 1 allele of
LCO1B1*5 and were assigned to simvastatin had a greater
ncidence of the CAE, and those assigned to atorvastatin
educed Function Alleles of Statin Pharmacokinetic Genes and FreTable 2 Reduced Function Alleles of Statin Pharmacokinetic G
SNP rsID Protein Effect Enzyme
CYP2D6*4 rs3892097 Spicing defect Reduced d
CYP2D6*10 rs1065852 Missense, S34P Decreased
CYP2C8*3 rs10509681 Missense, R399K Decreased
CYP2C8*4 rs1058930 Missense, M264I Decreased
CYP2C9*3 rs1057910 Missense, L395I Decreased
CYP3A4*1b rs2740574 392 AG Decreased
SLCO1B1*5 rs4149056 Missense, V174A Decreased
alues are n (%). *Unless otherwise by (reference number), enzymatic effects taken from http://w
rsID  reference sequence identification number; SNP  single nucleotide polymorphism; othehowed a similar trend when compared with those with no slleles. Interestingly, carriers of SLCO1B1*5 had no excess
ccurrence of the CAE if they were assigned to pravastatin
ompared with noncarriers. These trends were not, how-
ver, statistically significant (gene  treatment interaction,
 0.4). In contrast, the effect of female sex on the CAE
ppeared consistent across all 3 statins.
Changes in low-density lipoprotein (LDL) cholesterol
nd CK levels during the low- and high-dose phases of the
rial were measured. We found that the percent reduction in
DL cholesterol was similar for carriers and noncarriers of
LCO1B1*5 at both low- and high-dose treatment (statin-
djusted percent LDL reduction  SE in carriers vs.
oncarriers at low and high dose:31 1 vs.32 1 and
41  1 vs. 41  1, p  0.5 for both comparisons).
nalysis of CK levels revealed that there was an association
etween statin dose and marginally greater CK levels:
verage CK (mg/dl) at baseline, during low-dose, and
uring high dose phases: 121  81, 123  90, and 126 
2, repeated measures analysis of variance, p  0.004). In
he entire STRENGTH cohort, however, SLCO1B1*5
enotype was not associated with CK levels alone, neither
uring the low- nor high-dose phases (p  0.5).
In exploratory analyses to understand the statin-specific
ssociations of SLCO1B1*5 with the CAE, we measured
imvastatin and pravastatin acid and lactone concentrations
rom stored plasma samples (Table 3). Statin lactone con-
entrations in the STRENGTH study demonstrated no
ignificant differences by SLCO1B1*5 genotype for prava-
tatin or simvastatin at low or high doses (p  0.3 for all
omparisons). In contrast, the concentration of simvastatin
cid was positively correlated with SLCO1B1*5 both at 20
p  0.006) and 80 mg (p  0.03). This pattern, however,
as not evident for pravastatin acid (p  0.5). When we
ested for a gene statin interaction, there was a suggestion
or statistical evidence with low dose statin acid concentra-
ions (gene  treatment interaction p value  0.21) when
sing the more liberal alpha threshold as has been proposed
or evaluating interactions (23,24). With respect to sex,
here were no significant differences in statin acid or lactone
oncentrations at low dose or high doses of simvastatin or
ravastatin (p  0.5 for all comparisons).
To assess whether SLCO1B1*5 was associated with mild
cy in the STRENGTH Studyand Frequency in the STRENGTH Study
porter Effect*
Entire Cohort
(n  452)
CAE
(n  99)
No CAE
(n  353)
aploinsufficiency 142 (32) 34 (34) 108 (31)
161 (36) 40 (40) 121 (35)
94 (21) 15 (15) 79 (23)
46 (10) 8 (8) 38 (11)
47 (11) 14 (14) 33 (9)
60 (13) 14 (14) 46 (13)
123 (28) 35 (35) 88 (25)†
palleles.ki.se. †p  0.03.
viations as in Table 1.quenenes
/Trans
ue to h
(29)
(10)ide effects without significant CK elevations, we limited the
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October 20, 2009:1609–16 Pharmacogenetics of Statin Side Effectsopulation to either the 90 cases with CK levels 3 the
pper limit of normal (9 cases with CK 3 the upper
imit of normal excluded) or the 71 cases with musculoskel-
tal side effects (remaining 18 with gastrointestinal side
ffects coded as controls). In these analyses, the association
f SLCO1B1*5 and sex with mild side effects either re-
ained or were strengthened (Table 4). Finally, when we
ncluded those subjects who received study drug but were
riginally excluded (n  57, coded as control subjects),
emale sex and carrier status continued to be associated with
he CAE (p  0.003 and p  0.04, respectively).
iscussion
n this study, we sought to identify common, functional
enetic variants in drug-metabolizing enzymes or a he-
atic transporter that were associated with a composite
easure of mild statin-induced side effects in a large,
rospective pharmacogenetics statin challenge study in
hich one of the primary objectives was understanding
tatin safety. We defined a CAE as discontinuation for
ny side effect, the development of myalgia, and CK
Figure 1 Statin Stratified Analyses of Adverse Events
Percentage and number of those with the CAE outcome in the STRENGTH study st
is displayed. Carriers of SLCO1B1*5 appear to have no excess risk of CAE when a
all 3 statins. CAE  composite adverse event; STRENGTH  Statin Response Exalevation 3 upper limit of normal. We found that farriers of the reduced function allele (*5) of the organic
cid transporter SLCO1B1 and female subjects were at
reater risk of developing this CAE. This finding not
nly confirms the association with simvastatin-induced
yopathy with CK elevations identified in a genome
ide association study (14) but also expands this associ-
tion to the most common statin-induced side effects
e.g., myalgia or muscle ache without significant CK
levations) in a population treated with various statins.
urther, we found that the risk of the CAE was greatest
n those SLCO1B1*5 carriers assigned to simvastatin and
egligible in those assigned to pravastatin and is consis-
ent with our observation that the acid metabolite con-
entration of the drug was elevated in carriers who received
imvastatin but not in subjects receiving pravastatin.
Although the precise mechanisms for statin-induced side
ffects are unknown, they likely are caused by a combination
f patient and statin characteristics. Several patient-specific
isk characteristics have been identified such as older age,
educed body mass, hypothyroidism, and female sex (7).
ur findings are consistent with a previous association of
by SLCO1B1*5 genotype (top) and sex (bottom) for each assigned statin type
ed to pravastatin, whereas female patients appear to have an increased risk with
by Genetic Haplotype Markers.ratified
ssign
minedemale sex and simvastatin-induced myopathy (14). The
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Pharmacogenetics of Statin Side Effects October 20, 2009:1609–16eason for the effect of sex is unclear, but one study
dentified greater concentrations of pravastatin in women
han in men (13). In STRENGTH, we found no associa-
ion between sex and statin metabolite concentrations (Table
). Further, the association of female sex with the CAE in this
nalysis appeared consistent across statin types. These obser-
ations suggest that the mechanism for the increased risk of
ide effects in women may not relate to altered statin pharma-
okinetics or statin-specific characteristics.
Whether statin-induced side effects are class effects has
een debated. Cerivastatin, according to some, has the
reatest risk of musculoskeletal side effects, especially rhab-
omyolysis, when compared with other statins (25). In the
resent study, we observed that carriers of SLCO1B1*5 had
o excess risk of adverse events if assigned to pravastatin,
ven though the CAE rates were the same for all 3 statins.
here are 2 likely reasons why carriers appear to tolerate
ravastatin better than simvastatin. First, we showed that
fter 8 weeks of statin therapy, carriers accumulate greater
oncentrations of simvastatin acid but not pravastatin acid.
lthough both statins are substrates for SLCO1B1 (11,13),
hese studies have all been performed after single-dose
imvastatin and Pravastatin Metabolite Concentrations in the STRTable 3 Simvastatin and Pravastatin Metabolite Concentration
Sex
Metabolite Male Female
Simvastatin acid (20 mg) 28 30
1.7 [0.8–2.9] 1.1 [0.4–2.1
Simvastatin lactone (20 mg) 28 30
0.5 [0.2–1.0] 0.4 [0.3–0.8
Simvastatin acid (80 mg) 27 26
4.1 [1.5–8.2] 3.5 [1.6–5.3
Simvastatin lactone (80 mg) 27 26
1.3 [0.7–4.0] 1.2 [0.8–2.4
Pravastatin acid (10 mg) 28 25
0.2 [0.1–0.6] 0.2 [0.1–0.5
Pravastatin lactone (10 mg) 25 23
0.01 [0.01–0.02] 0.02 [0.01–0.
Pravastatin acid (40 mg) 29 24
1.2 [0.6–3.6] 0.9 [0.4–1.9
Pravastatin lactone (40 mg) 29 25
0.06 [0.03–0.11] 0.05 [0.02–1.
ach cell contains the number tested, median (ng/ml), 25th and 75th percentiles [in brackets], and
cross genotypes.
N/A  no available sample; other abbreviations as in Table 1.
ensitivity Analyses Using Various End-Point DefinitionsTable 4 Sensitivity Analyses Using Various End-Point Definition
Factor
Drug Discontinuation Due to
Side Effect  Muscle Sympto
CK >3 ULN (n  99)
SLCO1B1*5 p value 0.03
Chi-square statistic 4.8
Female sex p value 0.004
Chi-square statistic 8.4LN  upper limit of normal.hallenge studies. We speculate that during extended statin
herapy there may be alternative, compensatory routes of
limination for pravastatin (e.g., renal) such that carriers of
he *5 allele are protected from drug accumulation. Second,
he 2 statin metabolites differ markedly in their in vitro
yotoxicity such that simvastatin acid is nearly 10-fold
ore myotoxic than pravastatin acid (26). Therefore, the
reater exposure to simvastatin acid, a potentially more myo-
oxic metabolite compared with pravastatin acid, may mediate,
n part, the side effects observed in carriers assigned to
imvastatin. These results, however, need to be evaluated in
ther, larger populations and, if replicated, prescribing prava-
tatin would be a reasonable first choice for patients who carry
LCO1B1*5 to avoid statin-induced side effects. The more
otent statins could then be reserved for those who do not
chieve their LDL goals.
tudy limitations. Despite the interesting findings of the
resent study, there are several limitations that deserve
ention. First, our finding for SLCO1B1*5 in a dominant
odel does not survive correction for multiple comparisons
sing the FDR. However, our analysis was conservative in 3
ays: SNPs that belonged to CYP2D6 were treated as
H Studyhe STRENGTH Study
SLCO1B1 Genotype
*1/*1 *1/*5 *5/*5
28 27 3
1.2 [0.5–2.1] 1.4 [0.7–2.9] 11.2 [7.9–17.2]
0.006*
28 27 3
0.5 [0.3–1.0] 0.4 [0.2–0.9] 0.4 [0.2–0.6]
28 24 1
3.7 [1.3–5.3] 3.7 [1.6–9.2] 77.5 0.03*
28 24 1
1.1 [0.8–3.5] 1.4 [0.7–3.3] 3.7
25 27 1
0.2 [0.07–0.5] 0.2 [0.1–0.5] 0.2
23 24 1
0.02 [0.01–0.03] 0.01 [0.01–0.02] 0.002
26 27 N/A
1.0 [0.4–2.1] 1.0 [0.5–3.6]
26 27 N/A
0.07 [0.02–0.14] 0.05 [0.03–0.10]
where appropriate (based on linear regression on log transformed values). *p value for comparison
Drug Discontinuation
Due to Any Side Effect 
Muscle Symptoms (n  90)
Drug Discontinuation Due to
Musculoskeletal Side Effect 
Muscle Symptoms (n  71)
0.01 0.03
8.9 4.5
0.0002 0.0001
14.1 14.4ENGTs in t
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isequalibrium in STRENGTH Caucasian subjects they
re not truly independent; the tests of SLCO1B1*5 and the
ther variants might logically have been 1-sided because of
he known direction of their function; and the test of a gene
ose effect increases the statistical significance of
LCO1B1*5’s effect. Moreover, SLCO1B1*5 was associated
ith simvastatin myopathy in a genome-wide association
tudy with a much stronger level of association (p  1 
09) (27); therefore, our results are confirmatory of this
nitial report. Consistently, in STRENGTH, the associa-
ion of SLCO1B1*5 with adverse events in patients assigned
o simvastatin appeared to be the strongest.
Second, we had no placebo control arm as part of the
tudy. Several placebo-controlled trials of statins demon-
trate that a significant proportion of patients assigned to
lacebo experience adverse events at rates comparable with
hose assigned to statin (28,29). Therefore, in the present
tudy, we cannot quantify the attributable risk of AEs in
arriers of SLCO1B1*5. However, we can calculate the
elative risk of AEs in carriers versus noncarriers and our
stimates are similar in magnitude to those obtained from
he recently reported genome-wide association study of
imvastatin-induced myopathy (27).
Finally, we used a composite end point that reflects mild
tatin-induced side effects that developed during the trial.
owever, when we limited the analysis to those without
ignificant CK elevation or those with only musculoskeletal
ymptoms without CK elevations, the association with
LCO1B1*5 holds (Table 3).
There were several methodological strengths to our ap-
roach. First, we provided a clear biological rationale for the
andidate genes and SNPs of interest based on known statin
harmacogenetics. By choosing genes implicated in statin
harmacology and SNPs that were known to be functional
n prior studies we limited the number of statistical tests
eing performed and the risk of finding a false-positive
esult. For example, the SLCO1B1*5 allele has been well
tudied with respect to leading to greater statin drug
oncentrations (11–13) and was identified as a major cause
f simvastatin-induced myopathy with CK elevations (14).
econd, our hypothesis was tested within the context of a
arge, prospective statin pharmacogenetics challenge study.
he main benefit of such a trial is to provide clear,
onsistent, a priori definitions of the clinical phenotype of
nterest in order to minimize misclassification error. In
ddition, all subjects were followed, interviewed, and as-
essed in the identical manner therefore minimizing poten-
ial biases. Lastly, we provide in vivo data of statin metab-
lites that parallel the clinical associations.
onclusions
verall, statins are well-tolerated medications, although a
ortion of patients experience AEs that limit dose escala-
ion, statin adherence, and ultimately achieving target LDLevels. We report here that carriers of the SLCO1B1*5 allele
re at a 2-fold relative risk of mild statin induced side effects,
he majority of which had normal CK levels. These results
ould have potential implications for clinical practice be-
ause the vast majority of patients who are intolerant of
tatins have mild symptoms without associated CK eleva-
ions. For these patients, our findings suggest that prava-
tatin, instead of simvastatin, may be a reasonable first
hoice statin for carriers of the SLCO1B1*5 allele, whereas
omen may benefit from increased surveillance for symp-
oms. However, further studies of the role of this variant
nd gender in statin adherence and prognosis, and of
tatin-specific effects are necessary.
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